Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a PhD student in the Institute of Chemical Biology EPSRC Centre for Doctoral Training (CDT) in Chemical Biology, at Imperial College London.

When mass spectrometry redefines the pharma industry

In this new episode of omg OMx, Kate Stumpo speaks to Bruker’s Mike Greig about the incredible potential of mass spectrometry in pharma.

January 12, 2024

Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists | Psychedelic Invest

Vancouver, British Columbia–(Newsfile Corp. – June 27, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Health Canada-approved,

June 27, 2024

Genetic clue to pericarditis inflammation points to promising new treatments

Sequence variants that protect against pericarditis have been discovered at a genomic locus encoding interleukin-1 immune cytokines.

December 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.